title: CKD-602. Chong Kun Dang.
abstract: Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II trials of CKD-602 were underway.
authors.affiliation: Stichting Apotheek Haarlemse Ziekenhuizen, Boerhaavelaan 24, 2035 RC Haarlem, Amsterdam, The Netherlands. mcrul@sahz.nl
authors.forename: Mirjam
authors.initials: M
authors.lastname: Crul
mesh_terms: D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013678:Technology, Pharmaceutical / Q000379:methods; D059004:Topoisomerase I Inhibitors
chemical_list: D015507:Drugs, Investigational; D059004:Topoisomerase I Inhibitors; C116963:belotecan; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin